RNAi-Based Screening Professors and Supervisors in Germany

Michael Boutrosمشاهده پروفایل

استاد

German Cancer Research CenterGermany

Michael Boutros is a Full Professor at Heidelberg University and Head of Division at the German Cancer Research Center (DKFZ). He currently serves as Dean of the Medical Faculty at Heidelberg University (since 2023) and Director of the Marsilius Kolleg (since 2020). He has held leadership roles including Coordinator of the Functional and Structural Genomics Program at DKFZ (2014–2023) and Acting Scientific Director (2015–2016). His academic base is within the Medical Faculty, focusing on molecular oncology and functional genomics. PhD, Witten/Herdecke University (1993–1996) Postdoctoral Research, Harvard Medical School (1999–2003) MPA, John F. Kennedy School of Government, Harvard University (1999–2001) Additional training: Cold Spring Harbor Laboratory, SUNY Stony Brook His research centers on Wnt signaling, functional genomics, and cancer pathways. He leads major research initiatives such as CRC 1324 on Wnt signaling and the ERC Synergy Grant DECODE. His work integrates high-throughput screening, CRISPR, and systems biology to dissect signaling networks in cancer and development. He has pioneered genome-wide RNAi and CRISPR screens to identify novel regulators of Wnt signaling across models. The 15 most recent articles reflect a strong focus on Wnt pathway regulation using functional genomics in both Drosophila and mammalian systems. Themes include high-throughput screening, CRISPR-based validation, cross-species conservation, and therapeutic targeting. Keywords span Cancer Biology, Systems Biology, and Signal Transduction, with subfields like RNAi, ubiquitination, stem cell regulation, and machine learning in image analysis. Michael Boutros has received numerous scientific honors: Elected member, Leopoldina National Academy of Sciences (2022) Elected member, Heidelberg Academy of Sciences (2022) EMBO Member (2013) ERC Advanced Grant (2012) Johann-Georg Zimmermann Research Award (2007) EMBO Young Investigator (2005) Member, 'Die Junge Akademie' (2003) He has been a recipient of the Emmy-Noether Program, McCloy Fellowship, Boehringer Ingelheim PhD Fellowship, Studienstiftung Fellowship, and Fulbright Fellowship. As a mentor and research leader, he has supervised numerous early-career scientists and coordinated large collaborative grants including the FP7 'CancerPathways' project. He currently serves as Speaker of the Research and Strategy Commission at Heidelberg University and Managing Director of the Health and Life Science Alliance Heidelberg Mannheim. He leads the CRC 1324 on Wnt signaling and is Coordinating PI of the ERC Synergy Grant DECODE. He is also Spokesperson of DFG Research Group 1036 and Coordinator of the former FP7 Coordinated Project 'CancerPathways'. His lab employs cutting-edge functional genomics tools to decode signaling networks in cancer and development.

پروفایل رسمی دانشگاه

Sven-Erik Behrensمشاهده پروفایل

استاد

Martin Luther University Halle-WittenbergGermany

Prof. Dr. Sven-Erik Behrens serves as a Professor in the Department of Microbial Biotechnology at the Faculty of Natural Sciences I of Martin Luther University Halle-Wittenberg. He is affiliated with the Protein Research Center 'Charles Tanford' and maintains an active research program focused on RNA biology, molecular virology, and biotechnological applications. His primary research interests encompass RNA-based plant protection strategies, viral replication mechanisms (particularly for flaviviruses and plant viruses), and innovative vaccine development using Kluyveromyces lactis yeast expression systems. Behrens' work investigates fundamental RNA-protein interactions, RNA chaperone activities, and the molecular basis of antiviral defense mechanisms in plants. His laboratory explores how RNA accessibility influences viral replication and how this knowledge can be harnessed for developing novel RNA-based antiviral strategies. Analysis of his recent publications (2021-2025) reveals a clear research trajectory focused on identifying accessible RNA sites for targeted antiviral applications, optimizing yeast-based vaccine platforms for both plant and animal pathogens, and investigating the role of non-coding RNAs in plant development and stress responses. His work spans multiple disciplines including plant virology, medical virology, and microbial biotechnology, demonstrating translational research from basic molecular mechanisms to practical applications. Prof. Behrens leads research in the Department of Microbial Biotechnology, collaborating with various groups working on plant-pathogen interactions and vaccine development. His laboratory employs advanced techniques including RNA structure probing, fluorescence-based assays for RNA chaperone activity, and plant in vitro systems for studying viral replication. The research demonstrates significant potential for developing novel approaches to combat viral diseases in both agricultural and medical contexts.

پروفایل رسمی دانشگاه

Jens Peter von Kriesمشاهده پروفایل

پژوهشگر

Leibniz-Institut für Molekulare PharmakologieGermany

Dr. Jens Peter von Kries is the Head of the Screening Unit at the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin, Germany, within the Research Section of Chemical Biology. He leads a high-throughput screening platform that provides open-access services for academic and small-to-medium enterprise (SME) research projects. His research focuses on high-throughput screening (HTS) technologies, including biochemical and cell-based assays, automated liquid handling systems (Tecan, Beckman Coulter), acoustic dispensing, and advanced data analysis using R, Python, and KNIME workflows. His work supports drug discovery through services such as primary screening, hit validation, IC50 determination, LC-MS quality control, and Surface Plasmon Resonance (SPR) binding studies. He also oversees RNAi and CRISPR-based genetic screening and high-content imaging. A recent publication in Frontiers in Neurology (2023) highlights his involvement in studying the role of endothelial dysfunction and ACE-2 in SARS-CoV-2 pathogenesis and post-COVID neurological damage, indicating an expanding interest in the intersection of molecular pharmacology and neuroinfectious diseases. The publications analyzed show a strong emphasis on translational chemical biology , combining advanced screening technologies with mechanistic insights into disease pathways, particularly in virology and vascular biology. His work bridges assay development, data science, and biomedical application. Lead researcher in high-throughput screening and automation Expertise in assay development and validation for drug discovery Active contributor to research on molecular mechanisms of viral infections Dr. von Kries collaborates with academic teams and manages a multidisciplinary technical team within the Screening Unit. The facility operates as a core technology platform, supporting a wide range of external and internal research projects, with an emphasis on open access and scientific collaboration.

پروفایل رسمی دانشگاه

Yuriy Sheludkoمشاهده پروفایل

پژوهشگر

Technical University of DarmstadtGermany

Dr. Yuriy Sheludko is a Researcher in the Warzecha Lab at Darmstadt University of Technology, specializing in Plant Biotechnology and Metabolic Engineering. His work focuses on transient expression systems, enzyme engineering, and secondary metabolite biosynthesis in plants. Primary Affiliation: Warzecha Lab, Darmstadt University of Technology Research Pillars: Metabolic Pathway Engineering, Enzyme Evolution, Plant Synthetic Biology Research Interests span transient gene expression, heterologous biosynthesis of pharmaceutical alkaloids, and engineering plant systems for rapid protein production. He has pioneered methods using Nicotiana species for Agrobacterium-mediated expression of human enzymes like cytochrome P450s. Publication Trends show sustained contributions to plant-based biopharmaceuticals, with recent work (2022-2025) emphasizing substrate-specific enzyme engineering and synthetic promoter systems. His studies bridge fundamental alkaloid biosynthesis and applied molecular farming. Labs & Collaborations : Central figure in the Warzecha Lab, advancing transient expression platforms and collaborating on transgenic crop development projects.

پروفایل رسمی دانشگاه

Maik Jörg Lehmannمشاهده پروفایل

استاد

Bingen University of Applied SciencesGermany

Prof. Dr. Maik Jörg Lehmann is a Professor of Biochemistry, Cell Biology, and Microbiology at Technische Hochschule Bingen. He holds roles such as Deputy Chairman of the Examination Board for Biotechnology and Biological Safety Officer. His academic journey includes a PhD in Molecular Biology from Ruprecht-Karls-University Heidelberg (2002), postdoctoral research at Yale University School of Medicine, and leadership roles at institutes like the Humboldt University of Berlin and the German Cancer Research Center. He specializes in pathogen-cell interactions, RNAi-based screening, and advanced microscopy techniques. Research Focus: His work focuses on identifying host factors in viral infections through RNAi screens, visualizing pathogen dynamics using fluorescence and electron microscopy, and developing 3D cell culture models. Key projects involve collaborations with institutions like Yale University and the Wellcome Trust Center for Human Genetics. Awards: Recipient of the Klaus-Georg und Sigrid Hengstberger Prize (2007) for early-career scientists and the Teaching Excellence Award (2015) at Humboldt University. Grants & Labs: Leads research on HIV entry mechanisms, Plasmodium biology, and host-pathogen interactions. His lab employs cutting-edge imaging and bioinformatics tools to study cellular processes and viral replication.

پروفایل رسمی دانشگاه

David A. Scheinbergمشاهده پروفایل

استاد

University of TrierGermany

David A. Scheinberg, MD, PhD, is a physician-scientist and Professor at Weill-Cornell Medical College and Memorial Sloan Kettering Cancer Center (MSK). He holds the Vincent Astor Chair and serves as Deputy Director for Therapeutic Discovery at the Sloan Kettering Institute (SKI), Chair of the Experimental Therapeutics Center, and co-chair of the Pharmacology Graduate Program. His research focuses on immunotherapy, cancer vaccines, and targeted therapies, including monoclonal antibodies, alpha particle therapies, and nanotechnology-based treatments. He has developed eight therapeutic agents that advanced to clinical trials, such as first-in-class antibodies for acute leukemia and targeted alpha therapies. Education: MD/PhD from Johns Hopkins School of Medicine. Residencies at New York Hospital/Cornell, fellowship at MSK. Board-certified in Internal Medicine and Medical Oncology. Research Interests: Discovery of novel immunotherapies, including TCR-mimic antibodies targeting intracellular oncogenic proteins (e.g., WT1), targeted radiopharmaceuticals, and nanodevices. His work spans leukemia, solid tumors, and cellular resistance mechanisms. Notable contributions include the first humanized anti-leukemia antibodies and alpha particle therapies. Awards: Includes the Doris Duke Distinguished Clinical Science Professorship, Emil J. Freireich Award, and election to prestigious societies like the American Society of Clinical Investigation. Grants & Collaborations: Founded the Tri-Institutional Therapeutics Discovery Institute (MSK, Cornell, Rockefeller) and Experimental Therapeutics Center. Active in biotech advisory roles and clinical trials. His lab oversees multiple projects, including CAR T-cell engineering and targeted nanomedicines. Labs/Teams: Directs the David Scheinberg Lab within SKI's Molecular Pharmacology Program, collaborating across departments and institutions to translate discoveries into clinical applications.

پروفایل رسمی دانشگاه

Andreas Linkermannمشاهده پروفایل

استاد

Heidelberg UniversityGermany

Professor Andreas Linkermann holds the Chair of Nephrology at Heidelberg University's Mannheim Medical Faculty and directs the Fifth Department of Medicine at Mannheim University Hospital. His work integrates clinical care, research, and teaching across nephrology, transplantation medicine, endocrinology, and pulmonology. Research focuses on regulated cell death mechanisms (ferroptosis, necroptosis) in kidney diseases, acute organ injury, and transplant preservation. Key contributions include elucidating gasdermin D's role in immunothrombosis and defining ferroptosis pathways in metabolic and cardiovascular disorders. He leads translational projects on biomarkers for normothermic organ perfusion and sex-based differences in acute kidney injury. As a clinical leader, he oversees multidisciplinary teams advancing precision medicine approaches in renal and metabolic diseases. Research interests span cell death immunogenicity, STING signaling in inflammation, and therapeutic targeting of lipid peroxidation. His work bridges basic science and clinical applications, with recent emphasis on ferroptosis modulation in diabetes, ischemia-reperfusion injury, and cancer cell vulnerability. He collaborates with the Mannheim Medical Technology Campus and contributes to Baden-Württemberg's healthcare innovation initiatives.

پروفایل رسمی دانشگاه

Gary Bruce Ruvkunمشاهده پروفایل

استاد

Max Planck Institute for MathematicsGermany

Gary Bruce Ruvkun (born March 26, 1952) is an American molecular biologist currently serving as a professor of genetics at Harvard Medical School and conducting research at Massachusetts General Hospital in Boston. His groundbreaking work in molecular biology has earned him numerous prestigious awards, including the 2024 Nobel Prize in Physiology or Medicine. Ruvkun received his Bachelor of Arts in biophysics from the University of California, Berkeley in 1973 and his PhD in biophysics from Harvard University in 1982. His doctoral research was conducted under Frederick M. Ausubel, focusing on bacterial nitrogen fixation genes. He completed postdoctoral research with Robert Horvitz at MIT and Walter Gilbert at Harvard. Ruvkun's research has fundamentally transformed our understanding of gene regulation through microRNAs. His laboratory discovered the mechanism by which the first microRNA, lin-4, regulates translation of target mRNAs via imperfect base-pairing, and identified the second microRNA, let-7, demonstrating its conservation across animal phylogeny including humans. His work revealed an entirely new world of RNA regulation at an unprecedented small size scale. Additionally, Ruvkun's laboratory discovered key features of insulin-like signaling pathways that control aging and metabolism in C. elegans, with homologues now implicated in human aging and diabetes. His publication record spans over decades, with major contributions in microRNA biology, gene regulation, aging mechanisms, and more recently, astrobiology through the SETG (Search for Extraterrestrial Genomes) project. His articles show a progression from fundamental molecular mechanisms to broader applications in medicine and even space exploration. Major Scientific Awards Nobel Prize in Physiology or Medicine (2024) Wolf Prize in Medicine (2014) Lasker Award for Basic Medical Research Gairdner Foundation International Award Benjamin Franklin Medal in Life Science Breakthrough Prize in Life Sciences (2015) Member of National Academy of Sciences (2008) Ruvkun has collaborated extensively with Victor Ambros throughout his career, with whom he shared many awards for their co-discovery of microRNAs. His laboratory at Harvard Medical School continues to explore fundamental questions in molecular biology, aging, and the potential for extraterrestrial life. The SETG project, developed in collaboration with Maria Zuber at MIT, Chris Carr, and Michael Finney, aims to develop instruments that can amplify and sequence DNA and RNA to search for life on other planets that might be ancestrally related to Earth's Tree of Life.

پروفایل رسمی دانشگاه